Log in

BioSpecifics Technologies Stock Price, News & Analysis (NASDAQ:BSTC)

$48.78
-0.56 (-1.13 %)
(As of 10/20/2019 04:00 PM ET)
Today's Range
$47.90
Now: $48.78
$49.51
50-Day Range
$48.41
MA: $54.27
$58.93
52-Week Range
$47.90
Now: $48.78
$73.31
Volume48,188 shs
Average Volume44,014 shs
Market Capitalization$357.56 million
P/E Ratio17.87
Dividend YieldN/A
Beta1.21
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.96 million
Cash Flow$3.05 per share
Book Value$13.41 per share

Profitability

Net Income$20.05 million

Miscellaneous

Employees6
Market Cap$357.56 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.


BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) posted its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.15. The biopharmaceutical company earned $8.85 million during the quarter, compared to analyst estimates of $8.98 million. BioSpecifics Technologies had a net margin of 63.06% and a return on equity of 21.97%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 analysts have issued 12-month price targets for BioSpecifics Technologies' stock. Their forecasts range from $90.00 to $90.00. On average, they expect BioSpecifics Technologies' stock price to reach $90.00 in the next twelve months. This suggests a possible upside of 84.5% from the stock's current price. View Analyst Price Targets for BioSpecifics Technologies.

What is the consensus analysts' recommendation for BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioSpecifics Technologies.

Has BioSpecifics Technologies been receiving favorable news coverage?

News coverage about BSTC stock has trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioSpecifics Technologies earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for BioSpecifics Technologies.

Are investors shorting BioSpecifics Technologies?

BioSpecifics Technologies saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 246,800 shares, a decline of 9.5% from the August 30th total of 272,700 shares. Based on an average trading volume of 51,100 shares, the short-interest ratio is presently 4.8 days. Currently, 4.6% of the shares of the company are sold short. View BioSpecifics Technologies' Current Options Chain.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Dr. Ronald Law J.D., Ph.D., Interim Principal Exec. Officer (Age 66)
  • Mr. Patrick M. Caldwell, Interim Principal Financial Officer (Age 57)
  • Carl A. Valenstein, Corp. Sec.

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Roubaix Capital LLC (0.53%), Navellier & Associates Inc (0.22%), CIBC Private Wealth Group LLC (0.09%), Bowling Portfolio Management LLC (0.09%), Winfield Associates Inc. (0.07%) and Nisa Investment Advisors LLC (0.05%). Company insiders that own BioSpecifics Technologies stock include Jennifer M Chao, Mark N Wegman, Of Edwin H Wegman Estate, Patrick M Caldwell, Paul Gitman, Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Which major investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, CIBC Private Wealth Group LLC, Navellier & Associates Inc and Bowling Portfolio Management LLC. Company insiders that have sold BioSpecifics Technologies company stock in the last year include Jennifer M Chao, Mark N Wegman, Of Edwin H Wegman Estate, Patrick M Caldwell, Paul Gitman and Toby Wegman. View Insider Buying and Selling for BioSpecifics Technologies.

Which major investors are buying BioSpecifics Technologies stock?

BSTC stock was acquired by a variety of institutional investors in the last quarter, including Winfield Associates Inc., Nisa Investment Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $48.78.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $357.56 million and generates $32.96 million in revenue each year. The biopharmaceutical company earns $20.05 million in net income (profit) each year or $2.73 on an earnings per share basis. BioSpecifics Technologies employs 6 workers across the globe.View Additional Information About BioSpecifics Technologies.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is http://www.biospecifics.com/.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (NASDAQ BSTC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: No Load Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel